NCT04678557View on ClinicalTrials.gov

A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

November 12, 2021

Study Completion Date

November 19, 2021

Conditions
Type 1 Diabetes
Interventions
COMBINATION_PRODUCT

VC-01 Combination Product

PEC-01 cells loaded into an Encaptra Drug Delivery System

Trial Locations (4)

30318

Atlanta Diabetes Associates, Atlanta

78731

Texas Diabetes & Endocrinology, Austin

92025

AMCR Institute, Escondido

94598

Diablo Clinical Research, Walnut Creek

Sponsors

Lead Sponsor

ViaCyte
All Listed Sponsors
lead

ViaCyte

INDUSTRY